Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

Bibliography

• GALLIENI M, BRANCACCIO D, PADOVESE P et al.: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int. (1992) 42:1191-1198.
   PubMedGoogle Scholar
• DRESSLER R, LAUT J, LYNN RI, GINSBERG N: Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin. Nephrol. (1995) 43:324-331.
   PubMedGoogle Scholar
• SLATOPOLSKY E, BERKOBEN M, KELBER J et al.: Effects of calcitriol and non-calcemia vitamin D analogs on secondary hyperparathyroidism. Kidney Int. Suppl. (1992)38:S43.
   Google Scholar
• MALBERTI F, CORRADI B, COSCI P, CALLIADA F, MARCELLI D, IMBASCIATI E: Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparthyroidism. Am. J. Kidney Dis. (1996) 28:704-712.
   PubMedGoogle Scholar
• REICHEL H, DEIBERT B, SCHMIDT-GAYK H, RITZ E: Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol. Dial. Transplant. (1991) 6:162-169.
   PubMed Web of Science ®Google Scholar
• PITTS TO, PIRAINO BH, MITRO R et al.: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J. Clin. Endocrinol. Metab. (1988) 67:876-881.
   PubMed Web of Science ®Google Scholar
• SLATOPOLSKY E, BROWN A, DUSSO A: Pathogenesis of secondary hyperparathyroidism. Kidney Int. Suppl. (1999) 56:S14-S19.
   Google Scholar
• SLATOPOLSKY D, BROWN A, DUSSO A: Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am. J. Kidney Dis. (2001) 37(Suppl. 2): S54-S57.
   PubMedGoogle Scholar
• SLATOPOLSKY E, FINCH J, DENDA M et al.: Phosphorus restriction prevents parathyroid gland growth: high phosphorus directly stimulates PTH secretion in vitro. J. Clin. Invest. (1996) 97:2534-40.
   PubMed Web of Science ®Google Scholar
• ALMADEN Y, CANALEJO A, HERNANDEZ A et al.: Direct effect of phosphorus on PTH secretion from whole rat parathyroid gland in vitro. J. Bone Miner. Res. (1996) 11:970-976.
   PubMed Web of Science ®Google Scholar
• DENDA M, FINCH J, SLATOPOLSKY E: Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am. J. Kidney Dis. (1996) 28:596-602.
   PubMed Web of Science ®Google Scholar
• SILVER J, NAVEH-MANY T, MAYER H et al.: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest. (1986) 78:1296-1301.
   PubMed Web of Science ®Google Scholar
• RUSSELL J, LETTIERI D, SHERWOOD LM: Suppression by 1,25 (OH) D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology (1986) 119:2864-2866.
   PubMed Web of Science ®Google Scholar
• GOGUSEV J, DUCHAMBON P, HORY B et al.: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. (1997) 51:328-336.
   PubMed Web of Science ®Google Scholar
• FUKADA N, TANAKA H, TOMINAGA Y, FUKAGAWA M, KUROKAWA K, SEINO Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremia patients. J. Clin. Invest. (1993) 92:1436-1443.
   PubMedGoogle Scholar
• COZZOLINO M, BRANCACCIO D, GALLIENI M, SLATOPOLSKY E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. (2005) 68:429-436.
   PubMed Web of Science ®Google Scholar
• KETTLER M, GROSS M, RITZ E: Calcification and cardiovascular problems in renal failure. Kidney Int. (2005) 67(Suppl. 94):S120-S127.
   Web of Science ®Google Scholar
• BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31:607-617.
   PubMed Web of Science ®Google Scholar
• GANESH SK, STACK AG, LEVIN NW et al.: Association of elevated serum PO(4), CaxPO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. (2001) 12:2131-2138.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, KLASSEN PS, LAZARUS JM, OFSTHUN N, LOWRIE EG, CHERTOW GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15:2208-2218.
   PubMed Web of Science ®Google Scholar
• NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for bone metabolism in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S1-S201.
   PubMedGoogle Scholar
• MEE AP, DAVENPORT LK, HOYLAND JA, DAVIES M, MAWER EB: Novel and sensitive detection systems for the vitamin D receptor – in situ reverse transcriptase-polymerase chain reaction and immunogold cytochemistry. J. Mol. Endocrinol. (1996) 16:183-196.
   PubMed Web of Science ®Google Scholar
• DUSSO AS, BROWN AJ: Mechanisms of vitamin D action and its regulation. Am. J. Kidney Dis. (1998) 32(Suppl.):13-24.
   Web of Science ®Google Scholar
• GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcifications in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2003) 342:1478-1483.
   Web of Science ®Google Scholar
• QUNIBI WY, NOLAN CA, AYUS JC: Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int. Suppl. (2002) 82:73-80.
   Web of Science ®Google Scholar
• MALLIK NP, BERLYNE GM: Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet (1968) 2:1316-1320.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH D, RITZ E, COVIC A: Vascular calcification: a stiff challenge for the nephrologist; does preventing bone disease cause arterial disease? Kidney Int. (2004) 66:1315-1333.
   PubMed Web of Science ®Google Scholar
• COBURN J, MAUNG H, ELANGOVAN L et al.: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am. J. Kidney Dis. (2004) 43(5):877-890.
   PubMed Web of Science ®Google Scholar
• SLATOPOLSKY E, FINCH J, RITTER C et al.: A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am. J. Kidney Dis. (1995) 26:852-860.
   PubMed Web of Science ®Google Scholar
• HOLLIDAY LS, GLUCK SL, SLATOPOLSKY E, BROWN AJ: 1,25-Dihydroxy-19-nor-vitamin D (2), a vitamin D analog with reduced bone resorbing activity in vitro. J. Am. Soc. Nephrol. (2000) 11:1857-1864.
   PubMed Web of Science ®Google Scholar
• FINCH JL, BROWN AJ, SLATOPOLSKY E: Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin-D2 on calcium and phosphorus resorption in bone. J. Am. Soc. Nephrol. (1999) 10:980-985.
   PubMed Web of Science ®Google Scholar
• MARTIN KJ: Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double blind, multicenter, radomized study. Am. J. Kidney Dis. (2001) 38(Suppl.):S57-S63.
   PubMed Web of Science ®Google Scholar
• SPRAGUE SM: Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am. J. Kidney Dis. (2001) 38(Suppl.):S51-S56.
   PubMed Web of Science ®Google Scholar
• LLACH F, YUDD M: Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathydoisim. Am. J. Kidney Dis. (2001) 38(Suppl.):S45-S50.
   PubMed Web of Science ®Google Scholar
• TENG M, WOLF M, LOWRIE E, OFSTHUN N, LAZARUS M, THADHANI R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New Engl. J. Med. (2003) 349:446-456.
   PubMed Web of Science ®Google Scholar
• COYNE DW, ACHARYA M, QIU P et al.: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am. J. Kidney Dis. (2006) 47(2):263-276.
   PubMed Web of Science ®Google Scholar
• QUARLES LD, YOHAY DA, CARROLL BA et al.: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. (1994) 45:1710-1721.
   PubMed Web of Science ®Google Scholar
• LEVINE BS, SONG M: Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J. Am. Soc. Nephrol. (1996) 7:488-496.
   PubMedGoogle Scholar
• QUARLES LD, INDRIDASON OS: Calcitriol administration in end-stage renal disease: intravenous or oral? Pediatr. Nephrol. (1996) 10:331-336.
   PubMedGoogle Scholar
• HAMDY NA, KANIS JA, BENETON MN et al.: Effect of alfacalcidol on natural course of renal bone disease in mild and moderate renal failure. Br. Med. J. (1995) 310(6976):358-363.
   PubMed Web of Science ®Google Scholar